Get the Stockscreener App
27.52
2.93%
-0.83
Apellis Pharmaceuticals Inc stock is traded at $27.52, with a volume of 1.12M.
It is down -2.93% in the last 24 hours and down -8.66% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$28.35
Open:
$28.68
24h Volume:
1.12M
Relative Volume:
0.48
Market Cap:
$3.42B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-13.56
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+0.44%
1M Performance:
-8.66%
6M Performance:
-30.95%
1Y Performance:
-58.86%
1-Day Range:
$27.46
$28.98
1-Week Range:
$27.45
$28.98
52-Week Range:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
27.52 | 3.42B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
High Growth Tech Stocks In The United States To Watch - Yahoo Finance
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now? - Yahoo Finance
Sobi, Apellis Seek EMA Nod for Expanded Use of Aspaveli in Rare Kidney Diseases - Marketscreener.com
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment - Marketscreener.com
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals chief people officer sells shares worth $37,178 - MSN
10 Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis stock jumps as rare kidney disease therapy succeeds in trial - MSN
Apellis Pharmaceuticals' chief people officer sells $53,275 in stock - MSN
Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
HC Wainwright Reaffirms Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares - MarketBeat
Savant Capital LLC Purchases 9,407 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Entropy Technologies LP Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Banque Pictet & Cie SA - MarketBeat
Raymond James maintains Strong Buy on Apellis shares, target at $78 - MSN
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 60% as the stock sheds US$248m this past week - Simply Wall St
(APLS) Investment Analysis and Advice - Stock Traders Daily
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals to Hold Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Raymond James maintains Strong Buy on Apellis shares, target at $78 By Investing.com - Investing.com South Africa
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week - Yahoo Finance
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock By Investing.com - Investing.com UK
Apellis Pharmaceuticals Officer Sells Shares to Cover Taxes - TradingView
Piper Sandler maintains neutral on Apellis stock, $32 target - MSN
APLSApellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes - br.ADVFN.com
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Addition... - br.ADVFN.com
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results - br.ADVFN.com
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in ... - br.ADVFN.com
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN - br.ADVFN.com
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - br.ADVFN.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):